A randomized, open-label, single-dose, 2-way cross-over study to compare the safety and the pharmacokinetic characteristics of CPBI402 in healthy male volunteers
Latest Information Update: 18 Sep 2019
At a glance
- Drugs CPBI 402 (Primary)
- Indications Genitourinary disorders
- Focus Pharmacokinetics
- Sponsors Corepharmbio
- 08 Sep 2016 New trial record